Semler Scientific (NASDAQ:SMLR) Trading Down 3.1% – Time to Sell?

Semler Scientific, Inc. (NASDAQ:SMLR)’s stock price traded down 3.1% on Thursday . The stock traded as low as $67.62 and last traded at $69.08. 60,779 shares changed hands during trading, a decline of 80% from the average session volume of 298,413 shares. The stock had previously closed at $71.28.

Semler Scientific Trading Down 9.6 %

The company has a market cap of $586.32 million, a P/E ratio of 30.86 and a beta of 1.17. The business has a 50 day moving average price of $51.29 and a 200-day moving average price of $37.15.

Semler Scientific (NASDAQ:SMLR) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.35. Semler Scientific had a net margin of 27.00% and a return on equity of 20.31%. The firm had revenue of $13.51 million for the quarter.

Hedge Funds Weigh In On Semler Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of SMLR. Newbridge Financial Services Group Inc. acquired a new stake in shares of Semler Scientific in the second quarter valued at approximately $34,000. Quest Partners LLC acquired a new stake in Semler Scientific during the 2nd quarter valued at $59,000. Meeder Asset Management Inc. acquired a new stake in Semler Scientific during the 2nd quarter valued at $67,000. US Bancorp DE boosted its position in Semler Scientific by 60.8% during the third quarter. US Bancorp DE now owns 3,064 shares of the company’s stock worth $72,000 after purchasing an additional 1,158 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in shares of Semler Scientific in the third quarter valued at $104,000. Institutional investors own 49.37% of the company’s stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.